Skip to content
Brand AI

Monopar Therapeutics

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2026

    Monopar Therapeutics appoints Jeffrey D. Kent as Executive Vice President, Head of Medical Affairs

    Monopar Therapeutics announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. Kent will lead the company's medical affairs organization as Monopar prepares for potential FDA approval of the New Drug Application for ALXN1840 for Wilson disease.

    Source